BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Intra-Cellular Therapies readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Intra-Cellular Therapies's drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06480383-708@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06480383)
DESCRIPTION:Deulumateperone\, phase 2\, Generalized Anxiety Disorder.\nStud
 y: Study of ITI-1284 as an Adjunctive Treatment in Patients With Generaliz
 ed Anxiety Disorder\nEstimated primary completion: 16 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/deulumateperone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06480383
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05850689-872@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT05850689)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Major Depressive Disorder.\n
 Study: Study of Lumateperone as Adjunctive Therapy in the Treatment of Pat
 ients With Major Depressive Disorder\nEstimated primary completion: 5 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0585
 0689
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06690398-872@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06690398)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3.\nStudy: Multicenter Study of 
 Lumateperone for the Treatment of Irritability Associated With Autism Spec
 trum Disorder in Pediatric Patients\nEstimated primary completion: 21 June
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06690
 398
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706674-872@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270621
DTEND;VALUE=DATE:20270622
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06706674)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3.\nStudy: Multicenter Study of 
 Lumateperone for the Treatment of Irritability Associated With Autism Spec
 trum Disorder (ASD) in Pediatric Patients\nEstimated primary completion: 2
 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lumatepe
 rone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06706674
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06701903-708@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20271014
DTEND;VALUE=DATE:20271015
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06701903)
DESCRIPTION:Deulumateperone\, phase 2\, Generalized Anxiety Disorder.\nStud
 y: Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized
  Anxiety Disorder\nEstimated primary completion: 14 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/deulumateperone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06701903
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651567-708@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06651567)
DESCRIPTION:Deulumateperone\, phase 2\, Alzheimer's Disease Agitation.\nStu
 dy: A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment
  of Agitation Associated With Alzheimer's Dementia\nEstimated primary comp
 letion: 28 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/deulumateperone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06651567
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06540833-708@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Deulumateperone: Phase 2 readout est. (NCT06540833)
DESCRIPTION:Deulumateperone\, phase 2\, Alzheimer's Disease.\nStudy: A Stud
 y to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psycho
 sis Associated With Alzheimer's Disease\nEstimated primary completion: 30 
 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/deulu
 mateperone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06540833
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07747389-872@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20290920
DTEND;VALUE=DATE:20290921
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT07747389)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Major Depressive Disorder.\n
 Study: A Study of Lumateperone Versus Placebo in Participants With Major D
 epressive Disorder\nEstimated primary completion: 20 September 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lumateperone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07747389
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807865-708@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300218
DTEND;VALUE=DATE:20300219
SUMMARY:Deulumateperone: Phase 3 readout est. (NCT07807865)
DESCRIPTION:Deulumateperone\, phase 3\, Generalized Anxiety Disorder.\nStud
 y: A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as 
 an Additional Treatment in Participants With Generalized Anxiety Disorder 
 (GAD)\nEstimated primary completion: 18 February 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/deulumateperone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07807865
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07856420-708@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20300920
DTEND;VALUE=DATE:20300921
SUMMARY:Deulumateperone: Phase 3 readout est. (NCT07856420)
DESCRIPTION:Deulumateperone\, phase 3\, Generalized Anxiety Disorder.\nStud
 y: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Partic
 ipants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Resp
 onse to GAD Treatment\nEstimated primary completion: 20 September 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/deulumateperone#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07856420
URL:https://assetmemo.bio/drug/deulumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06372964-872@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06372964)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Bipolar Depression.\nStudy: 
 Multicenter Study of Lumateperone for the Treatment of Bipolar Depression 
 in Pediatric Patients\nEstimated primary completion: 31 October 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lumateperone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06372964
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06229210-872@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20320428
DTEND;VALUE=DATE:20320429
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06229210)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Schizophrenia.\nStudy: Safet
 y and Tolerability Trial of Lumateperone in Pediatric Patients With Schizo
 phrenia\, Bipolar Disorder or Autism Spectrum Disorder\nEstimated primary 
 completion: 28 April 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lumateperone#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06229210
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
